Adolescent Psychiatry Inpatients: Self-reported Parent-adolescent Communication Quality and Treatment Outcome

October 8, 2024 updated by: Universitätsklinikum Hamburg-Eppendorf

Adolescent Psychiatry Inpatients: Self-reported Parent-adolescent Communication Quality As a Predictor of Treatment Outcome

The quality of parent-adolescent communication has been found to be associated with adolescent mental health. However, little is known about the association of parent-adolescent communication and adolescent mental health in the context of psychiatry inpatient treatment.

This study aims to find out whether self-reported parent-adolescent communication quality at the time of admission to psychiatry predicts the treatment outcome in terms of symptom reduction 6 months later in an adolescent inpatient sample. It also aims to track changes in adolescent self-reported communication quality in the course of inpatient treatment and afterwards (2, 4 and 6 months after admission) to see whether improvement predicts treatment outcome, with treatment outcome being defined as symptom reduction to baseline. As a secondary endpoint, it will be assessed whether a placement of the adolescent outside the family was considered during treatment and whether self-reported communication quality at the time of admission predicts the consideration of placement outside the family.

Study Overview

Detailed Description

The main hypotheses of the study are:

1a Higher quality of self-reported parent-adolescent communication at baseline is positively associated with higher symptom reduction from baseline (psychiatry admission, t0) to 6 months after admission (t3).

  1. b Higher improvement of parent-adolescent communication from t0 to t3 is positively associated with higher symptom reduction from t0 to t3.
  2. Higher quality of self-reported parent-adolescent communication at baseline is negatively associated with consideration of the adolescent's placement outside the family during treatment.

The hypotheses 1a and 1b will be assessed with a linear regression model, hypothesis 2 will be assessed with a logistic regression model.

Covariates that will be taken into consideration are symptom severity at baseline, socioeconomic status of the family, adolescent gender, age, and comorbidity. Sensitivity analyses will be calculated for inpatient treatment duration and outpatient treatment duration after discharge from the hospital.

Symptom severity as the primary outcome is assessed with three measures: YSR (Youth Self-Report), DISYPS-ANG (Diagnostik-System für Psychische Störungen - Angststörungen) and DISYPS-DES Diagnostik-System für Psychische Störungen - Depressive Störungen). The relevant scale will be chosen according to the primary clinical diagnosis: If the primary diagnosis is anxiety (F40-F41), DISYPS-ANG will be used for the primary outcome. If the primary diagnosis is depression (F32-F33), DISYPS-DES will be used. If any other condition is the primary diagnosis, the YSR total scale will be used. Raw values of the DISYPS and the YSR will be transformed into z-values.

Study Type

Observational

Enrollment (Estimated)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Holger Zapf, Dr
  • Phone Number: +49 176 8441 2529
  • Email: h.zapf@uke.de

Study Locations

      • Hamburg, Germany, 20246
        • Recruiting
        • University Medical Center Hamburg-Eppendorf

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adolescents aged 14;1 to 17;12 years with a diagnosis of a mental disorder requiring inpatient treatment at a psychiatric site.

Description

Inclusion Criteria:

  • Admission to inpatient care unit of the adolescent psychiatry at the University Medical Center Hamburg-Eppendorf.

Exclusion Criteria:

  • Severe symptom burden at admission
  • Lack of knowledge of the German language.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Study group (observation only)
Adolescent inpatients at the child and adolescent psychiatry, age 14-17 years.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in self-rated relevant symptoms according to the discharge diagnosis (general mental health)
Time Frame: From baseline to 6 months after admission (T3)
General mental health symptoms will be assessed with the YSR (Youth Self-Report). If a condition other than F32-33 or F40-41 is the primary diagnosis, the YSR total scale will be used. The YSR consists of 112 items, rated on a three-step scale. Higher values indicate higher symptom burden.
From baseline to 6 months after admission (T3)
Change in self-rated relevant symptoms according to the discharge diagnosis (depression symptoms)
Time Frame: From baseline to 6 months after admission (T3)
Depression symptoms will be assessed with the DISYPS-DES (Diagnostik-System für Psychische Störungen - Depressive Störungen). If the primary diagnosis is depression (F32-F33), DISYPS-DES will be used. The DISYPS-DES consists of consist of 29 items, rated on a four-step scale. Higher values indicate higher symptom burden.
From baseline to 6 months after admission (T3)
Change in self-rated relevant symptoms according to the discharge diagnosis (anxiety symptoms)
Time Frame: From baseline to 6 months after admission (T3)
Anxiety symptoms will be assessed with the DISYPS-ANG (Diagnostik-System für Psychische Störungen - Angststörungen). If the primary diagnosis is anxiety (F40-F41), DISYPS-ANG will be used for the primary outcome. The DISYPS-ANG consists of 44 items, rated on a four-step scale. Higher values indicate higher symptom burden.
From baseline to 6 months after admission (T3)
Discussion of external placement (rated by clinician)
Time Frame: From baseline to 6 months after admission (T3)
The responsible clinician rates whether an external placement (outside the family) of the adolescent was discussed in the context of psychiatric treatment (yes/no). It has to be considered as discussed ("yes") if either the adolescent, one parent or more or the treatment team articulate a wish/recommendation regarding external placement during the period of treatment toward any other party.
From baseline to 6 months after admission (T3)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in self-rated parent-adolescent communication quality
Time Frame: From baseline to 6 months after admission (T3)
PACS (Parent-Adolescent Communication Scale) questionnaire. The PACS consists of 20 items rated on a five-step scale and ranges from 20-100 with better values indicating higher communication quality.
From baseline to 6 months after admission (T3)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Holger Zapf, Dr, Universitatsklinikum Hamburg-Eppendorf

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 8, 2024

Primary Completion (Estimated)

July 7, 2026

Study Completion (Estimated)

October 30, 2026

Study Registration Dates

First Submitted

July 30, 2024

First Submitted That Met QC Criteria

October 8, 2024

First Posted (Estimated)

October 9, 2024

Study Record Updates

Last Update Posted (Estimated)

October 9, 2024

Last Update Submitted That Met QC Criteria

October 8, 2024

Last Verified

July 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • JuStCom

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anxiety

Subscribe